

De Novo *KAT5* Variants Cause a Syndrome with Recognizable Facial Dysmorphisms, Cerebellar Atrophy, Sleep Disturbance, and Epilepsy

Jonathan Humbert,^{1,11} Smrithi Salian,^{2,11} Periklis Makrythanasis,^{3,4,11} Gabrielle Lemire,² Justine Rousseau,² Sophie Ehresmann,² Thomas Garcia,² Rami Alasiri,⁵ Armand Bottani,⁶ Sylviane Hanquinet,⁷ Erin Beaver,⁸ Jennifer Heeley,⁸ Ann C.M. Smith,⁹ Seth I. Berger,¹⁰ Stylianos E. Antonarakis,⁴ Xiang-Jiao Yang,⁵ Jacques Côté,¹ and Philippe M. Campeau^{2,*}

Summary

KAT5 encodes an essential lysine acetyltransferase, previously called TIP60, which is involved in regulating gene expression, DNA repair, chromatin remodeling, apoptosis, and cell proliferation; but it remains unclear whether variants in this gene cause a genetic disease. Here, we study three individuals with heterozygous *de novo* missense variants in *KAT5* that affect normally invariant residues, with one at the chromodomain (p.Arg53His) and two at or near the acetyl-CoA binding site (p.Cys369Ser and p.Ser413Ala). All three individuals have cerebral malformations, seizures, global developmental delay or intellectual disability, and severe sleep disturbance. Progressive cerebellar atrophy was also noted. Histone acetylation assays with purified variant *KAT5* demonstrated that the variants decrease or abolish the ability of the resulting NuA4/TIP60 multi-subunit complexes to acetylate the histone H4 tail in chromatin. Transcriptomic analysis in affected individual fibroblasts showed deregulation of multiple genes that control development. Moreover, there was also upregulated expression of *PER1* (a key gene involved in circadian control) in agreement with sleep anomalies in all of the individuals. In conclusion, dominant missense *KAT5* variants cause histone acetylation deficiency with transcriptional dysregulation of multiples genes, thereby leading to a neurodevelopmental syndrome with sleep disturbance, cerebellar atrophy, and facial dysmorphisms, and suggesting a recognizable syndrome.

Introduction

Epigenetic regulation by histone acetylation is essential for proper development, and its role in human genetic diseases is increasingly being recognized. Notably, variants in lysine acetyltransferase genes, such as *KAT6A* (MIM: 601408) and *KAT6B* (MIM: 605880), have been identified in individuals with neurodevelopmental disorders characterized by intellectual disability and malformations.^{1,2} *KAT5* (MIM: 601409) (a.k.a. *TIP60*) variants have not yet been associated with a syndrome. *KAT5* can act as a haploinsufficient tumor suppressor gene, and it encodes an essential lysine acetyltransferase involved in gene expression, DNA repair, chromatin remodeling, apoptosis, and cell proliferation.^{3,4} It is part of a large, multi-protein complex named NuA4 (also known as the TIP60/p400 complex), which includes TRRAP, EP400, and ING3 among other proteins.⁵ Local recruitment of the NuA4 complex and *KAT5*-mediated acetylation of conserved lysine residues on histones H4 and H2A(.Z/.X) are linked to transcription activation as well as repair of DNA dou-

ble-strand breaks, in part through chromatin relaxation but also through signaling and/or crosstalk with other chromatin-binding factors.^{6,7} *KAT5* can also directly acetylate non-histone proteins such as ATM in DNA damage response, p53 at lysine 120 in apoptosis, and other mitotic regulators that impact cell cycle control. *KAT5*-dependent acetylation of specific transcription factors can also lead to transcription activation or repression.^{8–10} The NuA4/TIP60 complex is essential for stem cell maintenance and renewal,¹¹ and recent work revealed that *KAT5* may play a role in epithelial-mesenchymal transition induction¹²; all of these are key processes in the developing embryo. Finally, *KAT5* contributes to genome integrity by maintaining accurate chromosome alignment and segregation.¹³ *KAT5* depletion was shown to impair the chromosomal segregation during mitosis and to result in polyploidy.¹⁴

We studied three individuals with *de novo* heterozygous missense variants in *KAT5* that affect normally invariant residues. All three individuals have short stature, cerebral malformations, seizures, and global developmental delay

¹St-Patrick Research Group in Basic Oncology, Laval University Cancer Research Center, Axe Oncologie du Centre de Recherche du Centre Hospitalier Universitaire de Québec—Université Laval, Québec City, QC G1R 3S3, Canada; ²Sainte-Justine Hospital Research Center, University of Montreal, Montreal, QC H3T 1C5, Canada; ³Biomedical Research Foundation of the Academy of Athens, Athens 115 27, Greece; ⁴Department of Genetic Medicine and Development, University of Geneva Medical School and Geneva University Hospitals, 1211 Geneva, Switzerland; ⁵Rosalind and Morris Goodman Cancer Research Centre, Department of Medicine, McGill University, Montreal, QC H3A 1A3, Canada; ⁶Service of Genetic Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland; ⁷Unit of Pediatric Radiology, Geneva University Hospitals, 1211 Geneva, Switzerland; ⁸Mercy Kids Genetics, St. Louis, MO 63141, USA; ⁹Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20894, USA; ¹⁰Children's National Health System, Washington, DC 20010, USA

¹¹These authors contributed equally

*Correspondence: p.campeau@umontreal.ca

<https://doi.org/10.1016/j.ajhg.2020.08.002>

© 2020 American Society of Human Genetics.

or intellectual disability along with a significant speech disorder and a severe sleep disorder.

In order to understand the molecular mechanisms underlying the phenotype in these individuals with *KAT5* variants, we engineered cell lines to purify native NuA4 complexes that contain the variant catalytic subunit so that we could determine the possible effects on complex assembly/protein interactions and acetylation of chromatin substrates, and we performed transcriptomic analyses in primary cells to determine possible target genes implicated in the pathology.

Material and Methods

Recruitment and Sequencing

Apart from the published individual, other individuals were recruited through GeneMatcher.¹⁵ Information was obtained from each clinical team. Exome sequencing (ES) was performed by the National Institutes of Health (NIH) Intra-mural Sequencing Center (NISC) for individual 1 (complete method described by Berger et al.¹⁶). ES was performed on a research basis for individual 2 at University of Geneva Medical School and Geneva University Hospitals. ES was performed in a commercial laboratory for individual 3. Informed consent to publish clinical information and photographs was obtained from the parents of the individuals reported in this article. For each individual, the procedures followed were in accordance with the ethical standards of the responsible committees on human experimentation.

Cell Culture and Transfection

K562 cells were obtained from the American Type Culture Collection (ATCC) and maintained at 37°C under 5% CO₂ in RPMI medium supplemented with 10% newborn calf serum (Wisent) and GlutaMAX (Thermo Fisher). When cultivated in spinner flasks, 25 mM HEPES-NaOH (pH 7.4) was added. Cells were transfected using Lipofectamine 2000 (Thermo Fisher) per the manufacturer's instructions.

Generation of Stable Cell Lines Producing Tagged *KAT5* Variants and Affinity Purification of NuA4/TIP60 Complexes

KAT5 (461aa isoform) was cloned into the AAVS1_Puro_PGK1_3x-FLAG_Twin_Strep plasmid (addgene #68375), and the variants found in each individual were introduced via site-directed mutagenesis. Generation of K562 cells that expressed either wild-type (WT) or variant-tagged *KAT5* was performed through break-induced recombination and/or insertion at the *AAVS1* locus (MIM: 102699) as described.¹⁷

Nuclear cell extracts were prepared from 3.109 cells and used to perform tandem affinity purification as described.¹⁸ In brief, nuclear extracts were adjusted to 0.1% Tween-20, and ultracentrifuged at 100,000 g for 1 h. Extracts were precleared with 250 μ l Sepharose CL-6B (Sigma), then 250 μ l anti-FLAG M2 affinity resin (Sigma) was added for 2 h at 4°C. The beads were then washed in Poly-Prep columns (Bio-Rad) with 40 column volumes (CV) of buffer #1 (20 mM HEPES-KOH [pH 7.9], 10% glycerol, 300 mM KCl, 0.1% Tween 20, 1 mM DTT, 1 mM PMSF, 2 μ g/mL Leupeptin, 5 μ g Aprotinin, 2 μ g/mL Pepstatin, 10 mM Na-butyrate, 10 mM

β -glycerophosphate, 100 μ M Sodium Orthovanadate, 5 mM N-Ethylmaleimide, 2 mM Ortho-Phenanthroline) followed by 40 CV of buffer #2 (20 mM HEPES-KOH [pH 7.9], 10% glycerol, 150 mM KCl, 0.1% Tween 20, 1mMDTT, 1 mM PMSF, 2 μ g/mL Leupeptin, 5 μ g Aprotinin, 2 μ g/mL Pepstatin, 10 mM Na-butyrate, 10 mM β -glycerophosphate, 100 μ M Sodium Orthovanadate, 5 mM N-Ethylmaleimide, 2 mM Ortho-Phenanthroline). Complexes were eluted in two fractions with 2.5 CV of buffer #2 supplemented with 200 μ g/mL 3xFLAG peptide (Sigma) for 1 h at 4°C. Typically, 15 μ l of the first elution (3% of total) was loaded on NuPAGE 4%–12% Bis-Tris gels (Invitrogen) and analyzed via silver staining.

In Vitro HAT Assays

1 μ g of core histones (CH) or short oligonucleosomes (SON) was incubated with affinity-purified NuA4/TIP60 complexes harboring the different *KAT5* variants and ³H-labeled acetyl-CoA (0.1 μ Ci, Perkin-Elmer) in HAT buffer (50 mM Tris-HCl pH8.0, 50 mM KCl, 5% glycerol, 0.1 mM EDTA, 1 mM DTT, 1 mM PMSF, 10 mM Sodium Butyrate) for 30 min at 30°C. Half of the reaction was spotted on P81 filter paper, washed, and analyzed via liquid scintillation. The other half was loaded on SDS-PAGE 15% gels. Gels were Coomassie-stained to ensure homogeneous loading, then destained, fluorographed using EN³HANCE (Perkin-Elmer), dried, and exposed at –80°C. The amounts of purified TIP60/NuA4 complex used in the reactions were normalized between samples based on 3H counts on CH and Flag-*KAT5* signal measured via immunoblot. All reactions were done in triplicates, and the assay was performed two times.

RNaseq Methods

RNA libraries were prepared from low-passage fibroblasts from individuals 2 and 3 through the use of the Illumina RNA Truseq V2 and Truseq mRNA stranded kits, respectively. The libraries were then sequenced on an Illumina HiSeq4000 sequencer at 2 \times 100bp and 1 \times 100bp read lengths, respectively. Two and four healthy control low-passage fibroblasts were also sequenced from Truseq V2 and Truseq mRNA stranded libraries at 2 \times 100bp and 1 \times 100bp read lengths, respectively. Transcriptomics analyses were performed as previously described.¹⁹ Common differentially expressed genes were selected by using the DESeq2 R package to compare the affected individuals to the respective healthy controls with thresholds at |Log₂FC| > 0.5, 5% FDR, and adjusted p value < 0.05.

RT-qPCR

Total RNA from affected individuals and three new controls was isolated from low-passage fibroblasts through the use of the Pure-Link RNA mini kit (Life Technologies). Controls were male children of White, African American, and Asian backgrounds. Equal amounts of RNA were used to synthesize cDNA through the use of the qScript cDNA synthesis kit (Quanta Biosciences). cDNA was quantified through the use of PowerUp SYBR green Master Mix (Applied Biosystems) on a LightCycler® 96 system (Roche) using primers listed in Table S3. Amplicons were resolved by using agarose gel to determine the size. Relative gene expression levels were analyzed via 2^{– $\Delta\Delta$ CT} method with β -actin used as the reference gene. Statistical significance was determined via two-way ANOVA with Dunnett's multiple comparisons test. Variation was reported as standard deviation (SD).

Results

Clinical Descriptions

Individual 1 is a 30-year-old female with intellectual disability who has been reported by Berger et al. in a Smith-Magenis Syndrome (SMS)-like cohort.¹⁶ She presented with behavioral problems with perseverative speech, poor language function, and sleep disorder. At age 10, she had disruptive behaviors and a diagnosis of attention deficit disorder. At age 29, she had an IQ of 40 with expressive language at the 8-year-old level and receptive language at 4-to-5-year-old skill level. Her head circumference is 55cm (73rd centile). She also presents with adult-onset seizures, severe myopia, hyperacusis, kyphoscoliosis, brachydactyly, and frequent urinary tract infections. Her facial dysmorphisms include a round face with a flat facial profile, prognathism, down-slanting corners of the mouth, low-set ears, depressed nasal bridge, and almond-shaped eyes. She has partial agenesis of the corpus callosum. She developed secondary amenorrhea at 29 years of age. Sleep problems present since early childhood included early sleep offset, nighttime awakenings (1–2), and increased daytime naps. In adulthood, sleep diaries document 24 h sleep cycle characterized by early morning awakening (between 05:30–06:30), bedtime at 20:30, two daytime naps (09:30–10:30 and 13:00–14:30), and nocturnal awakenings (~30 min long) after sleep onset, usually occurring at 23:00 and 01:00. Increased daytime salivary melatonin level was documented at 11:15 (mean 46 pg/mL for two samples), which is consistent with the inverted circadian melatonin profile observed in SMS.²⁰ ES identified a *de novo* missense variant c.158G>A (p.Arg53His) in *KAT5* (RefSeq accession number NM_006388.3). No other variants met the filtering exome criteria.

Individual 2 is a 13-year-old male with intellectual disability and multiple malformations. He was born at 38 weeks with a unilateral cleft lip and palate. At 12 years of age, he is nonverbal, and a cognitive evaluation documented an IQ of 20–30. He has disruptive behavior with hyperactivity and multiple stereotypies. He suffers from generalized tonic-clonic seizures and has severe sleep disorder (with sleep onset delay and night waking). His head circumference was 50 cm (1st centile, –2.6 SD). Facial dysmorphisms include prognathism, lateral thinning of the eyebrows, macrostomia, thick lower lip, and bulbous and asymmetric nose. He also has bilateral single palmar creases and fifth finger clinodactyly, as well as unilateral cryptorchidism. Horseshoe kidney and bilateral vesico-ureteral reflux were diagnosed during childhood. Brain MRI showed global progressive cerebellar atrophy (vermis more than hemispheres), dysgenesis of corpus callosum (short, thickened, and hypoplasia of rostrum and splenium), and a small anterior pituitary gland. He suffers from growth hormone (GH) deficiency diagnosed at the age of 2 years and for which he is treated with GH injec-



tions. ES identified a *de novo* missense variant c.1105T>A (p.Cys369Ser) in *KAT5* (RefSeq NM_006388.3).

Individual 3 is a 2-year-old male with developmental delay and multiple malformations. At 16 months of age, he presented with short stature and congenital microcephaly, height 71.1 cm (<1st centile, –2.9 SD), weight 11.2 kg (48th centile), and head circumference 44.5 cm (<1st centile, –2.2 SD). He has severe developmental delay with disruptive behaviors and an important sleep disorder (night waking and sleep onset delay which was improved by nighttime clonidine, which was prescribed because daytime clonidine caused daytime sleepiness). He suffers from generalized myoclonic seizures. He has a perimembranous ventricular septal defect and a dysplastic pulmonary valve with supra- and valvular stenosis. He also has a high-arched palate with a submucous cleft. His genitourinary anomalies consist of hypospadias and bilateral cryptorchidism. His facial dysmorphisms include a round face with a flat facial profile, epiblepharon, epicanthal folds, down-slanting corners of the mouth, and upturned nose with depressed nasal bridge. He also has bilateral fifth finger clinodactyly. His medication includes risperidone and clonidine. Brain MRI showed polymicrogyria of right sylvian fissure, cystic dilation of 4th ventricle, and inferior cerebellar vermis atrophy. ES identified a *de novo* missense variant c.1237T>G (p.Ser413Ala) in *KAT5* (RefSeq NM_006388.3).

Additional clinical information is available for these three individuals in [Tables S1](#) and [S2](#) (for comparison of sleep disorder characteristics).

Analysis of the Variants

We named the variants through the use of isoform NM_006388.3 (513 amino acids) because it is highly expressed and is the canonical isoform in Uniprot.²¹ However, the longest isoform is NM_182710.2 (546 amino acids), and a commonly studied isoform is NM_182709.2 (also known as PLIP, 461 amino acids). All three variants are absent from the Genome Aggregation Database (gnomAD),²² and this absence indicates that these variants are not present in the more than 100,000 individuals from population genetic studies included in this database. As shown in [Figure 1B](#), the p.Arg53His variant is in the chromodomain, following an acetylated lysine residue. In addition to potentially affecting *KAT5*'s ability to interact with histones via its chromodomain, the p.Arg53His variant may disrupt the protein's structure and thus stability (as suggested by STRUM analysis,²³ and by the protein yields in K562 cell extracts shown in [Figure S1](#)). The p.Cys369Ser variant is near the Acetyl-CoA binding domain, and this residue has been shown to be critical for the catalysis of yeast Esa1 (*KAT5* ortholog) and other MYST-family acetyltransferases,²⁴ as well as for *KAT5* autoacetylation.²⁵ Finally, the p.Ser413Ala variant is in the Acetyl-CoA binding domain. All residues are invariant throughout evolution,



C

	Arg53 (Ind. 1)				Cys369 (Ind. 2)				Ser413 (Ind. 3)																		
Human	D	F	N	K	R	L	D	E	W	Y	N	V	A	C	I	L	T	L	L	G	L	L	S	Y	R	S	Y
Rhesus	D	F	N	K	R	L	D	E	W	Y	N	V	A	C	I	L	T	L	L	G	L	L	S	Y	R	S	Y
Mouse	D	F	N	K	R	L	D	E	W	Y	N	V	A	C	I	L	T	L	L	G	L	L	S	Y	R	S	Y
Dog	D	F	N	K	R	L	D	E	W	Y	N	V	A	C	I	L	T	L	L	G	L	L	S	Y	R	S	Y
Elephant	D	F	N	K	R	L	D	E	W	Y	N	V	A	C	I	L	T	L	L	G	L	L	S	Y	R	S	Y
Xenopus	G	F	N	K	R	L	D	E	W	Y	N	V	A	C	I	L	T	L	L	G	L	L	S	Y	R	S	Y
Zebrafish	D	F	N	K	R	L	D	E	W	Y	N	V	A	C	I	L	T	L	L	G	L	L	S	Y	R	S	Y
Lamprey	D	F	N	K	R	L	D	E	W	Y	N	V	A	C	I	L	T	L	L	G	L	L	S	Y	R	S	Y
Fruit fly	D	F	N	K	R	L	D	E	W	Y	N	V	A	C	I	L	T	M	L	G	L	L	S	Y	R	S	Y
C. elegans	D	C	N	R	R	L	D	E	W	Y	N	V	A	C	I	L	T	V	L	G	L	L	S	Y	R	S	Y
Yeast	N	Y	N	K	R	L	D	E	W	Y	N	V	A	C	I	L	T	L	L	G	L	L	S	Y	R	A	Y

Figure 1. Clinical Images and Variant Details

(A) Photographs of the three individuals, showing shared facial dysmorphisms. Individual 1 and individual 3 have round faces, flat facial profiles, down-slanting corners of their mouths, and depressed nasal bridges. Individual 1 and individual 2 have prognathism. The images on the right are sagittal MRI images for individual 2 at the indicated ages, showing progressive cerebellar atrophy (arrow).

(B) Variant location in functional domains of the KAT5 protein.

(C) Affected amino acids are invariant between different species.

and in fact, they are conserved down to yeast Esa1 (Figure 1C). An analysis of the 3D structure of KAT5 (Figure 2A) suggests that the p.Cys369Ser and p.Ser413Ala

variants may alter the interaction of the protein with Acetyl-CoA. This was also suggested by 3D mutation impact analysis using HOPE and VarSite.^{26,27}




Figure 2. Functional Impact of KAT5 Variants on the Native NuA4/TIP60 Acetyltransferase Complex

(A) Predicted variant location in 3D reconstruction of KAT5 protein. Annotations below the images refer to the RCSB PDB (Research Collaboratory for Structural Bioinformatics Protein Data Bank) structure IDs.

(B) Variant KAT5 proteins assemble in normal NuA4/TIP60 complexes. WT and variant KAT5 proteins were fractionated from nuclear extracts via tandem affinity purification. Purified fractions were loaded on gel and stained with silver. *Bone fide* NuA4/TIP60 subunits are identified on the right. Note: the isoform used for experiments was the commonly used 461-amino-acid isoform (RefSeq NM_182709.2), and thus variants are at positions 53, 317, and 361 in that protein, but for all figures, they were identified with the canonical isoform RefSeq NM_006388.3 numbering for consistency with the rest of the manuscript.

(C) *In vitro* histone acetylation assay performed with purified native WT and variant complexes. The graph shows the scintillation counts of the liquid assays with 3H-Acetyl-CoA with free core histones (CH) or native short oligonucleosomes (SON). Error bars represent standard deviations of technical replicates.

(D) Fluorograph of *in vitro* histone acetylation assays with native WT and variant complexes. Protein gels were treated with En3Hance, dried, and exposed on film to assess 3H-labeled protein bands and/or acetylation in order to visualize the effect on specific histones (lower panels). Coomassie stained gels are shown to control relative substrate amounts in the reactions (upper panels).

Expected versus observed counting of single-nucleotide changes in gnomAD show that *KAT5* is only moderately intolerant to loss-of-function (LoF) variants (pLI score [probability of being loss of function intolerant] 0.09; observed/expected [o/e] ratio 0.26 [90% confidence interval (CI): 0.15–0.47]).²² Moreover, fewer missense variants were observed than were expected (o/e ratio 0.44 [90% CI: 0.39–0.51] with a Z score of 3.61) (gnomAD v2.1.1). Regarding other assessments of *KAT5* as a gene potentially associated with a dominant disease, the %HI score (haploinsufficiency score from DECIPHER) is 4.47%. %HI scores below 10% indicate that a gene is more likely to be deleterious if haploinsufficient.²⁸ The *KAT5* P(AD) score is 0.996 (probability for a gene to carry dominant mutations from the DOMINO website, accessed June 2, 2020).³ A P(AD) score of 0.95 is highly associated with auto-

somal dominant inheritance through haploinsufficiency, gain of function, or dominant-negative effects.²⁹ An analysis of the affected residues performed through the use of Metadome and the MTR Gene Viewer suggested that all affected residues are intolerant to variations.^{30,31} Moreover, most pathogenicity prediction tools we used considered the variants to be likely pathogenic. That was the case for DANN,³² DEOGEN2, EIGEN, FATHMM-MKL, M-CAP, MutationAssessor, MutationTaster, and SIFT (scores from the dbNSFP³³ database except for DANN and analyzed through the Varsome website³⁴). The variants had CADD scores of 32, 27, and 26 respectively (scores 20 or above indicate that they are among the 1% most likely pathogenic variants in the genome).³⁵ The variants were also considered to be deleterious according to results from Rhapsody and MutPred2.^{36,37}

Purification and Biochemical Analysis of KAT5 Variants

In order to determine the effect of the variants on KAT5 protein interactome and enzymatic activity, we used genome editing to introduce WT and mutant KAT5 cDNAs at the safe harbor AAVS1 locus in human K562 cells.¹⁷ Equivalent accumulation of the C-terminally tagged proteins (3×Flag-2×Strep) was measured and clones were selected (Figure S2). Production in these clones is near physiological levels compared to endogenous KAT5. Native NuA4/TIP60 complexes were then obtained via tandem affinity purification.¹⁸ Analysis of the purified fractions through the use of protein gel, immunoblotting, and mass spectrometry showed that WT and variant KAT5 normally assemble into full stoichiometric NuA4/TIP60 complexes (Figure 2B). Then, the histone acetyltransferase (HAT) activity of the different complexes was measured *in vitro* with 3H-Acetyl-CoA using free CH or native chromatin (SON) as substrates. All variants displayed impaired HAT activity to varying degrees compared to WT KAT5 (Figures 2C–D). The p.Cys369Ser variant showed the most dramatic effect, being unable to acetylate both free histones and chromatin, as expected based on its localization in the catalytic site. On the other hand, the complexes containing KAT5 p.Arg53His and p.Ser413Ala variants are mostly defective in their HAT activity toward chromatin, not free histones (Figure 2C). Strikingly, as shown through the use of gel fluorography (Figure 2D), this defect is clearly more specific toward nucleosomal histone H4 tail acetylation, whereas H2A acetylation is still detected. Altogether, these data clearly demonstrate that the *de novo* variants detected in the individuals described above cripple the lysine acetyltransferase activity of KAT5, leading to partial loss of function *in vivo* and impairing the ability of the NuA4/TIP60 complex to properly acetylate its targets in a chromatin context. Based on KAT5's critical role in genome expression and maintenance, control of cell proliferation, and development, these variants are likely implicated in the neurodevelopmental defects seen in these individuals.

Transcriptomic Analyses

We performed an analysis of dysregulated genes in primary human fibroblasts from individuals 2 and 3, as described previously.¹⁹ From the RNaseq data (cutoff Log2FC of >0.5 or <−0.5, $p \gg 0.05$ [Figure 3A]), we selected genes which were involved in development, neuronal function, and circadian rhythm control, and we performed qPCR analysis with additional controls (Figure 3B and Figure S2). Genes which showed consistent downregulations were *LHX9* (MIM: 606066) and *KIRREL3* (MIM: 607761). Genes which showed consistent upregulations were *GFPT2* (MIM: 603865), *PER1* (MIM: 602260), and *HDAC4* (MIM: 605314).

Discussion

As shown in Table 1, Table S1, and Figure 1A, the three affected individuals share many features. They are moder-

ately short (−1.95 SD, −2.1 SD, and −2.9 SD) and two have microcephaly (−2.6 SD and −2.2 SD). They have severe developmental delay or moderate-to-severe intellectual disability. All three individuals present with disruptive behavior and have severe sleep disorders. All have night waking, and individuals 2 and 3 have sleep onset delay (improved by clonidine for individual 3), and individual 1 has daytime sleepiness. Individuals 1 and 2 have anomalies of the corpus callosum, individuals 2 and 3 have cerebellar atrophy, and individual 3 has focal polymicrogyria. Facial dysmorphisms, each present in at least two individuals, include a round face with a flat facial profile, a depressed nasal bridge, downturned corners of the mouth, and prognathism. Individual 2 has a cleft lip and palate, and individual 3 has a submucous cleft palate. All three individuals have genitourinary anomalies, including cryptorchidism, hypospadias, horseshoe kidney, and vesico-ureteral reflux. Although there is some clinical overlap between the individuals we studied and individuals with SMS, such as sleep disturbances and some facial dysmorphisms, there are also several differences, such as the seizures and genitourinary anomalies seen in all individuals here, which are present in only a minority of individuals with SMS. Progressive cerebellar atrophy and CNS malformations are not observed in SMS, whereas dental anomalies and broad hands are common in SMS and are not observed here, among other differences.

KAT5 variants cause histone acetylation deficiency and gene expression deregulation, and thereby lead to a neurodevelopmental syndrome with facial dysmorphisms, various malformations, and sleep disturbances. Berger et al.¹⁶ had already reported individual 1 in 2017 and had then proposed KAT5 as a candidate gene to explain the phenotype. The addition of two new individuals with overlapping phenotypes and having a KAT5 variant confirms the involvement of KAT5 in human diseases. The observed deficient histone acetylation by biochemical assays using native KAT5 complexes suggests an LoF mechanism during development. Mice heterozygous for a knockout *Kat5* allele have normal development, growth, and fertility in the literature.^{3,38,39} Heterozygous mice phenotyped by the International Mouse Phenotyping Consortium (IMPC) are also essentially normal (IMPC website accessed June 3, 2020).⁴⁰ Homozygous knockout mice are embryonic lethal both in the literature and the IMPC study. It is possible that in humans, haploinsufficiency for KAT5 does not lead to a syndrome, and it is even likely given that over 10 high-confidence LoF variants are found in gnomAD, but that missense variants abrogating KAT5 activity might cause a dominant deleterious effect. Moreover, regulatory mechanisms may lead to near-normal KAT5 protein levels in case of haploinsufficiency. This was observed in adipose tissue of *Kat5* haploinsufficient mice, in which *Kat5* mRNA was reduced to 50%, but protein levels were normal, and similar observations were also made in different tissues in other studies.^{39,41,42} We hypothesize that NuA4 complexes with inactive KAT5




Figure 3. RNaseq Was Performed on Fibroblasts from Individuals 2 and 3 and Six Healthy Controls

(A) Volcano plot showing common DEGs (differentially expressed genes) of individuals 2 and 3. Significant DEGs. The red line indicates a $-\log_{10}$ (adjusted p value) of 1.3 (padj of 0.05); and the blue line a \log_2 Fold Change of -0.05 and 0.05 . Significant DEGs shown in panel B are represented by red dots.

(B) Reverse transcriptase-qPCR analysis of specific genes deregulated in fibroblasts from three new controls and from individuals 2 and 3. β -actin was used as the reference gene. Triplicates were used. Error bars represent standard deviation. p values were generated through the use of two-way ANOVA with Dunnett's multiple comparisons test.

taining neurons of the hypothalamus that are essential for the normal regulation of sleep.⁴⁴ *LHX9* is downregulated in individuals with Pallister-Kalilian syndrome, a neurodevelopmental disorder.⁴⁵ *KIRREL3* is an IgSF-adhesion molecule implicated in synapse formation, synaptic transmission, and ultrastructure. It regulates mossy fiber synapse development in the hippocampus⁴⁶ and has been implicated in neurodevelopmental disorders.^{47,48}

GFPT2, *PER1*, and *HDAC4* were consistently upregulated in primary fibroblasts. *GFPT2* controls the flux of glucose into the hexosamine pathway involved in protein glycosylation. An individual with severe intellectual disability was reported with a *de novo* missense variant in this gene.⁴⁹ *PER1* is a key component of the circadian clock and acts as a transcriptional repressor.⁵⁰ *HDAC4* is a histone deacetylase which binds promoters through transcription factors MEF2C and MEF2D and represses transcription. Its deletion causes cognitive and behavioral issues often

have widespread epigenetic consequences (as suggested by our transcriptomic studies), whereas the presence of slightly fewer NuA4 complexes does not, but future studies, ideally *in vivo*, will be required to assess this hypothesis.

LHX9 and *KIRREL3* were consistently downregulated in primary fibroblasts. *LHX9* is important for thalamic neuronal differentiation.⁴³ Knockout mice have profound hypersomnolence, likely because *Lhx9* may be important for specification or survival of a subset of hypocretin-con-

associated with brachydactyly.⁵¹ Interestingly, genome-wide location analysis of the NuA4/TIP60 complex in human K562 cells previously reported its presence on the *PER1* and *HDAC4* genes (see Figure S3).⁷

Importantly, *KAT5* has been shown to be critical for learning and memory in *Drosophila*^{52–54} and has also been shown to control sleep in *Drosophila* by regulating axonal growth in pacemaker cells.⁵⁵ In addition, mammalian *KAT5* has recently been reported to be an important regulator of the circadian clock cycle through direct

Table 1. Main Clinical Features

Individuals	1	2	3
KAT5 variants (RefSeq NM_006388.3)	c.158G>A (p.Arg53His)	c.1105T>A (p.Cys369Ser)	c.1237T>G (p.Ser413Ala)
Chromosomal positions (hg19)	Chr11:65480402G>A	Chr11:65484393T>A	Chr11:65486132T>G
Age and gender	29-year-old female	13-year-old male	18-month-old male
Microcephaly	-	+	+
Developmental delay or intellectual disability	+, IQ 40	+, IQ 20–30	+, severe
Behavioral issues	ADHD, sleep disorder, disruptive behavior	ADHD, severe sleep disorder, multiple stereotypies and disruptive behavior	behavioral difficulties with tantrums and head banging
Seizures	+	+	+
Cerebral malformations	partial agenesis of the corpus callosum	corpus callosum dysgenesis, cerebellar atrophy	focal polymicrogyria, cerebellar atrophy
Urogenital anomalies	recurrent urinary tract infections	horseshoe kidney, vesico-ureteral reflux, cryptorchidism	hypospadias, cryptorchidism
Congenital heart defect	-	-	VSD, dysplastic pulmonary valve
Orofacial malformations	-	unilateral cleft lip and palate	submucous cleft palate
Ocular anomaly	severe myopia	strabismus and hypermetropia	epiblepharon
Dysmorphisms	round face, flat facial profile; down-slanting corners of mouth; depressed nasal bridge; prognathism; low-set ears; almond-shaped eyes	lateral thinning of eyebrows, macrostomia, bulbous and asymmetric nose, thick lower lip, prominent chin	round face, flat facial profile; down-slanting corners of mouth

action at gene promoters and BMAL1 acetylation.⁵⁶ Moreover, another HAT, ELP3, has also been associated with sleep anomalies in *Drosophila*,⁵⁷ and sleep deprivation induces the expression of *Hdac2* in rat hippocampi.⁵⁸ The role of epigenetics in the regulation of sleep has been reviewed by Quershi and Mehler in 2014.⁵⁹ Sleep disturbances not associated with sleep apnea are also seen in diseases caused by variants in epigenetic regulators. Dominant variants in or deletions of the histone deacetylase *HDAC4* have been implicated in the pathophysiology of chromosome 2q37 deletion syndrome (MIM: 600430), in which there is a sleep disturbance, and lead to reduced expression of *RAI1* (MIM: 607642), a gene for which variants cause the overlapping SMS (MIM: 182290).⁶⁰ SMS due to deletions of 17p11.2 or *RAI1* variants is associated with a recognized circadian sleep disorder characterized by an advanced sleep phase and inverted melatonin secretion profile.^{61,62} Autosomal dominant mental retardation type 1 (MIM: 156200) is caused by variants in *MBD5* (MIM: 611472) that encode Methyl-CpG-binding domain protein 5, which is part of a polycomb repressive complex that deubiquitinates a lysine of histone H2A. Interestingly, disturbed *PER1* levels were noted with both *MBD5* mutations and with SMS.^{63,64} Diseases caused by mutations in other epigenetic regulators are associated with sleep disturbances (*KDM5B* [MIM: 605393],⁶⁵ *MECP2* [MIM: 300005],⁶⁶ *EHMT1* [MIM: 607001], *KMT2C* [MIM: 606833], and *HDAC8* [MIM: 300269]⁶⁷), as well as several other genetic diseases.^{68–72}

Other HATs associated with Mendelian disorders are *KAT6A* and *KAT6B*. *KAT6A* variants cause autosomal dominant mental retardation 32 (MIM: 616268), and overlapping features with the syndrome described here include intellectual disability, microcephaly, epilepsy, and sleep disturbances.⁷³ *KAT6B* variants cause Genitopatellar syndrome (MIM: 606170) and Say-Barber-Biesecker-Young-Simpson (SBBYS) syndrome (MIM: 603736). Overlapping features with both of these syndromes include intellectual disability, microcephaly, and genital anomalies. Specifically, corpus callosum anomalies (for Genitopatellar syndrome) and cleft palate (for SBBYS syndrome) are overlapping features with the syndrome described here.⁷⁴

It will be interesting in the future to determine whether similar pathways are dysregulated in neuronal models of the various epigenetic disorders associated with sleep disturbances mentioned above, as this could perhaps lead to the development of better targeted therapies for such symptoms.

Data and Code Availability

RNaseq data are available on the National Center for Biotechnology Information (NCBI)'s Gene Expression Omnibus with accession number GSE154199.

Supplemental Data

Supplemental Data can be found online at <https://doi.org/10.1016/j.ajhg.2020.08.002>.

Acknowledgments

We thank all affected individuals and family members for their participation in this study. Work was supported by grants from the Canadian Institutes of Health Research (CIHR) to J.C. (FDN-143314). P.M.C. is supported by salary awards from the CIHR and the Fonds de Recherche Québec—Santé. J.C. holds the Canada Research Chair in Chromatin Biology and Molecular Epigenetics. S.E.A.'s laboratory was supported by a ChildCare Foundation grant and a Swiss National Science Foundation (SNSF) grant (163180).

Declaration of Interests

The authors declare no competing interests.

Received: March 27, 2020

Accepted: July 21, 2020

Published: August 20, 2020

Web Resources

DECIPHER, <https://decipher.sanger.ac.uk/>

DOMINO, <https://www.wfmb.unil.ch/domino/>

ExAC Browser, <http://exac.broadinstitute.org/>

GenBank, <https://www.ncbi.nlm.nih.gov/genbank/>

Gene Expression Omnibus (GEO) database, <https://www.ncbi.nlm.nih.gov/geo/>

gnomAD, <https://gnomad.broadinstitute.org/>

IMPC, <https://www.mousephenotype.org/>

OMIM, <https://www.omim.org>

Philippe Campeau's laboratory, <http://pcampeaulab.org>

References

1. Arboleda, V.A., Lee, H., Dorrani, N., Zadeh, N., Willis, M., Macmurdo, C.F., Manning, M.A., Kwan, A., Hudgins, L., Barthelmy, F., et al.; UCLA Clinical Genomics Center (2015). De novo nonsense mutations in *KAT6A*, a lysine acetyltransferase gene, cause a syndrome including microcephaly and global developmental delay. *Am. J. Hum. Genet.* **96**, 498–506.
2. Campeau, P.M., Kim, J.C., Lu, J.T., Schwartzentruber, J.A., Abdul-Rahman, O.A., Schlaubitz, S., Murdock, D.M., Jiang, M.M., Lammer, E.J., Enns, G.M., et al. (2012). Mutations in *KAT6B*, encoding a histone acetyltransferase, cause Genitopatellar syndrome. *Am. J. Hum. Genet.* **90**, 282–289.
3. Gorrini, C., Squatrito, M., Luise, C., Syed, N., Perna, D., Wark, L., Martinato, F., Sardella, D., Verrecchia, A., Bennett, S., et al. (2007). Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. *Nature* **448**, 1063–1067.
4. Avvakumov, N., and Côté, J. (2007). The MYST family of histone acetyltransferases and their intimate links to cancer. *Oncogene* **26**, 5395–5407.
5. Doyon, Y., and Côté, J. (2004). The highly conserved and multifunctional NuA4 HAT complex. *Curr. Opin. Genet. Dev.* **14**, 147–154.
6. Steunou, A.-L., Rossetto, D., and Côté, J. (2014). Regulating chromatin by histone acetylation. In *Fundamentals of chromatin* (Springer), pp. 147–212. https://doi.org/10.1007/978-1-4614-8624-4_4.
7. Jacquet, K., Fradet-Turcotte, A., Avvakumov, N., Lambert, J.P., Roques, C., Pandita, R.K., Paquet, E., Herst, P., Gingras, A.C., Pandita, T.K., et al. (2016). The TIP60 Complex Regulates Bivalent Chromatin Recognition by 53BP1 through Direct H4K20me Binding and H2AK15 Acetylation. *Mol. Cell* **62**, 409–421.
8. Xiao, H., Chung, J., Kao, H.Y., and Yang, Y.C. (2003). Tip60 is a co-repressor for STAT3. *J. Biol. Chem.* **278**, 11197–11204.
9. Bararia, D., Trivedi, A.K., Zada, A.A., Greif, P.A., Mulaw, M.A., Christopheit, M., Hiddemann, W., Bohlander, S.K., and Behre, G. (2008). Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha. *Leukemia* **22**, 800–807.
10. Huang, J., Stewart, A., Maity, B., Hagen, J., Fagan, R.L., Yang, J., Quelle, D.E., Brenner, C., and Fisher, R.A. (2014). RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis. *Oncogene* **33**, 3604–3611.
11. Fazio, T.G., Huff, J.T., and Panning, B. (2008). An RNAi screen of chromatin proteins identifies Tip60-p400 as a regulator of embryonic stem cell identity. *Cell* **134**, 162–174.
12. Fukagawa, A., Ishii, H., Miyazawa, K., and Saitoh, M. (2015). δ EF1 associates with DNMT1 and maintains DNA methylation of the E-cadherin promoter in breast cancer cells. *Cancer Med.* **4**, 125–135.
13. Mo, F., Zhuang, X., Liu, X., Yao, P.Y., Qin, B., Su, Z., Zang, J., Wang, Z., Zhang, J., Dou, Z., et al. (2016). Acetylation of Aurora B by TIP60 ensures accurate chromosomal segregation. *Nat. Chem. Biol.* **12**, 226–232.
14. Grézy, A., Chevillard-Briet, M., Trouche, D., and Escaffit, F. (2016). Control of genetic stability by a new heterochromatin compaction pathway involving the Tip60 histone acetyltransferase. *Mol. Biol. Cell* **27**, 599–607.
15. Sobreira, N., Schiettecatte, F., Valle, D., and Hamosh, A. (2015). GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum. Mutat.* **36**, 928–930.
16. Berger, S.I., Ciccone, C., Simon, K.L., Malicdan, M.C., Vilboux, T., Billington, C., Fischer, R., Introne, W.J., Gropman, A., Blacato, J.K., et al.; NISC Comparative Sequencing Program (2017). Exome analysis of Smith-Magenis-like syndrome cohort identifies de novo likely pathogenic variants. *Hum. Genet.* **136**, 409–420.
17. Dalvai, M., Loehr, J., Jacquet, K., Huard, C.C., Roques, C., Herst, P., Côté, J., and Doyon, Y. (2015). A Scalable Genome-Editing-Based Approach for Mapping Multiprotein Complexes in Human Cells. *Cell Rep.* **13**, 621–633.
18. Doyon, Y., and Côté, J. (2016). Preparation and Analysis of Native Chromatin-Modifying Complexes. *Methods Enzymol.* **573**, 303–318.
19. Cogné, B., Ehresmann, S., Beauregard-Lacroix, E., Rousseau, J., Besnard, T., Garcia, T., Petrovski, S., Avni, S., McWalter, K., Blackburn, P.R., et al.; CAUSES Study; and Deciphering Developmental Disorders study (2019). Missense Variants in the Histone Acetyltransferase Complex Component Gene *TRRAP* Cause Autism and Syndromic Intellectual Disability. *Am. J. Hum. Genet.* **104**, 530–541.
20. Chik, C.L., Rollag, M.D., Duncan, W.C., and Smith, A.C. (2010). Diagnostic utility of daytime salivary melatonin levels in Smith-Magenis syndrome. *Am. J. Med. Genet. A.* **152A**, 96–101.
21. UniProt Consortium (2019). UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res.* **47** (D1), D506–D515.

22. Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-Luria, A.H., Ware, J.S., Hill, A.J., Cummings, B.B., et al.; Exome Aggregation Consortium (2016). Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 536, 285–291.
23. Quan, L., Lv, Q., and Zhang, Y. (2016). STRUM: structure-based prediction of protein stability changes upon single-point mutation. *Bioinformatics* 32, 2936–2946.
24. Yan, Y., Harper, S., Speicher, D.W., and Marmorstein, R. (2002). The catalytic mechanism of the ESA1 histone acetyltransferase involves a self-acetylated intermediate. *Nat. Struct. Biol.* 9, 862–869.
25. Yang, C., Wu, J., and Zheng, Y.G. (2012). Function of the active site lysine autoacetylation in Tip60 catalysis. *PLoS ONE* 7, e32886.
26. Venselaar, H., Te Beek, T.A., Kuipers, R.K., Hekkelman, M.L., and Vriend, G. (2010). Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. *BMC Bioinformatics* 11, 548.
27. Laskowski, R.A., Stephenson, J.D., Sillitoe, I., Orengo, C.A., and Thornton, J.M. (2020). VarSite: Disease variants and protein structure. *Protein Sci.* 29, 111–119.
28. Huang, N., Lee, I., Marcotte, E.M., and Hurles, M.E. (2010). Characterising and predicting haploinsufficiency in the human genome. *PLoS Genet.* 6, e1001154.
29. Quinodoz, M., Royer-Bertrand, B., Cisarova, K., Di Gioia, S.A., Superti-Furga, A., and Rivolta, C. (2017). DOMINO: Using Machine Learning to Predict Genes Associated with Dominant Disorders. *Am. J. Hum. Genet.* 101, 623–629.
30. Wiel, L., Baakman, C., Gilissen, D., Veltman, J.A., Vriend, G., and Gilissen, C. (2019). MetaDome: Pathogenicity analysis of genetic variants through aggregation of homologous human protein domains. *Hum. Mutat.* 40, 1030–1038.
31. Traynelis, J., Silk, M., Wang, Q., Berkovic, S.F., Liu, L., Ascher, D.B., Balding, D.J., and Petrovski, S. (2017). Optimizing genomic medicine in epilepsy through a gene-customized approach to missense variant interpretation. *Genome Res.* 27, 1715–1729.
32. Quang, D., Chen, Y., and Xie, X. (2015). DANN: a deep learning approach for annotating the pathogenicity of genetic variants. *Bioinformatics* 31, 761–763.
33. Liu, X., Wu, C., Li, C., and Boerwinkle, E. (2016). dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs. *Hum. Mutat.* 37, 235–241.
34. Kopanos, C., Tsiolkas, V., Kouris, A., Chapple, C.E., Albarca Aguilera, M., Meyer, R., and Massouras, A. (2019). VarSome: the human genomic variant search engine. *Bioinformatics* 35, 1978–1980.
35. Rentzsch, P., Witten, D., Cooper, G.M., Shendure, J., and Kircher, M. (2019). CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 47 (D1), D886–D894.
36. Ponzoni, L., Peñaherrera, D.A., Oltvai, Z.N., and Bahar, I. (2020). Rhapsody: predicting the pathogenicity of human missense variants. *Bioinformatics* 36, 3084–3092.
37. Pejaver, V., Urresti, J., Lugo-Martinez, J., Pagel, K.A., Lin, G.N., Nam, H.-J., Mort, M., Cooper, D.N., Sebat, J., Iakoucheva, L.M., et al. (2017). MutPred2: inferring the molecular and phenotypic impact of amino acid variants. *bioRxiv*. <https://doi.org/10.1101/134981>.
38. Hu, Y., Fisher, J.B., Koprowski, S., McAllister, D., Kim, M.S., and Lough, J. (2009). Homozygous disruption of the Tip60 gene causes early embryonic lethality. *Dev. Dyn.* 238, 2912–2921.
39. Gao, Y., Hamers, N., Rakhshandehroo, M., Berger, R., Lough, J., and Kalkhoven, E. (2014). Allele compensation in tip60^{+/-} mice rescues white adipose tissue function in vivo. *PLoS ONE* 9, e98343.
40. Dickinson, M.E., Flenniken, A.M., Ji, X., Teboul, L., Wong, M.D., White, J.K., Meehan, T.F., Weninger, W.J., Westerberg, H., Adissu, H., et al.; International Mouse Phenotyping Consortium; Jackson Laboratory; Infrastructure Nationale PHE-NOMIN, Institut Clinique de la Souris (ICS); Charles River Laboratories; MRC Harwell; Toronto Centre for Phenogenomics; Wellcome Trust Sanger Institute; and RIKEN BioResource Center (2016). High-throughput discovery of novel developmental phenotypes. *Nature* 537, 508–514.
41. Fisher, J.B., Kim, M.S., Blinka, S., Ge, Z.D., Wan, T., Duris, C., Christian, D., Twaroski, K., North, P., Auchampach, J., and Lough, J. (2012). Stress-induced cell-cycle activation in Tip60 haploinsufficient adult cardiomyocytes. *PLoS ONE* 7, e31569.
42. Gehrking, K.M., Andresen, J.M., Duvick, L., Lough, J., Zoghbi, H.Y., and Orr, H.T. (2011). Partial loss of Tip60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model. *Hum. Mol. Genet.* 20, 2204–2212.
43. Peukert, D., Weber, S., Lumsden, A., and Scholpp, S. (2011). Lhx2 and Lhx9 determine neuronal differentiation and compartment in the caudal forebrain by regulating Wnt signaling. *PLoS Biol.* 9, e1001218.
44. Dalal, J., Roh, J.H., Maloney, S.E., Akuffo, A., Shah, S., Yuan, H., Wamsley, B., Jones, W.B., de Guzman Strong, C., Gray, P.A., et al. (2013). Translational profiling of hypocretin neurons identifies candidate molecules for sleep regulation. *Genes Dev.* 27, 565–578.
45. Kaur, M., Izumi, K., Wilkens, A.B., Chatfield, K.C., Spinner, N.B., Conlin, L.K., Zhang, Z., and Krantz, I.D. (2014). Genome-wide expression analysis in fibroblast cell lines from probands with Pallister Killian syndrome. *PLoS ONE* 9, e108853.
46. Martin, E.A., Muralidhar, S., Wang, Z., Cervantes, D.C., Basu, R., Taylor, M.R., Hunter, J., Cutforth, T., Wilke, S.A., Ghosh, A., and Williams, M.E. (2015). The intellectual disability gene Kirrel3 regulates target-specific mossy fiber synapse development in the hippocampus. *eLife* 4, e09395.
47. Kalsner, L., Twachtman-Bassett, J., Tokarski, K., Stanley, C., Dumont-Mathieu, T., Cotney, J., and Chamberlain, S. (2018). Genetic testing including targeted gene panel in a diverse clinical population of children with autism spectrum disorder: Findings and implications. *Mol. Genet. Genomic Med.* 6, 171–185.
48. Conrad, S., Demurger, F., Moradkhani, K., Pichon, O., Le Caignec, C., Pascal, C., Thomas, C., Bayart, S., Perlat, A., Dubourg, C., et al. (2019). 11q24.2q24.3 microdeletion in two families presenting features of Jacobsen syndrome, without intellectual disability: Role of FLI1, ETS1, and SENCR long noncoding RNA. *Am. J. Med. Genet. A.* 179, 993–1000.
49. Gilissen, C., Hehir-Kwa, J.Y., Thung, D.T., van de Vorst, M., van Bon, B.W.M., Willemsen, M.H., Kwint, M., Janssen, I.M., Hoischen, A., Schenck, A., et al. (2014). Genome sequencing identifies major causes of severe intellectual disability. *Nature* 511, 344–347.

50. Franken, P., and Dijk, D.J. (2009). Circadian clock genes and sleep homeostasis. *Eur. J. Neurosci.* *29*, 1820–1829.
51. Le, T.N., Williams, S.R., Alaimo, J.T., and Elsea, S.H. (2019). Genotype and phenotype correlation in 103 individuals with 2q37 deletion syndrome reveals incomplete penetrance and supports HDAC4 as the primary genetic contributor. *Am. J. Med. Genet. A.* *179*, 782–791.
52. Schmidt, R.L., and Sheeley, S.L. (2015). Mating and memory: an educational primer for use with “epigenetic control of learning and memory in *Drosophila* by Tip60 HAT action”. *Genetics* *200*, 21–28.
53. Xu, S., Wilf, R., Menon, T., Panikker, P., Sarthi, J., and Elefant, F. (2014). Epigenetic control of learning and memory in *Drosophila* by Tip60 HAT action. *Genetics* *198*, 1571–1586.
54. Xu, S., and Elefant, F. (2015). Tip off the HAT- Epigenetic control of learning and memory by *Drosophila* Tip60. *Fly (Austin)* *9*, 22–28.
55. Pirooznia, S.K., Chiu, K., Chan, M.T., Zimmerman, J.E., and Elefant, F. (2012). Epigenetic regulation of axonal growth of *Drosophila* pacemaker cells by histone acetyltransferase tip60 controls sleep. *Genetics* *192*, 1327–1345.
56. Petkau, N., Budak, H., Zhou, X., Oster, H., and Eichele, G. (2019). Acetylation of BMAL1 by TIP60 controls BRD4-P-TEFb recruitment to circadian promoters. *eLife* *8*, e43235, 10.7554/eLife.43235.
57. Singh, N., Lorbeck, M.T., Zervos, A., Zimmerman, J., and Elefant, F. (2010). The histone acetyltransferase Elp3 plays an active role in the control of synaptic bouton expansion and sleep in *Drosophila*. *J. Neurochem.* *115*, 493–504.
58. Duan, R., Liu, X., Wang, T., Wu, L., Gao, X., and Zhang, Z. (2016). Histone Acetylation Regulation in Sleep Deprivation-Induced Spatial Memory Impairment. *Neurochem. Res.* *41*, 2223–2232.
59. Qureshi, I.A., and Mehler, M.F. (2014). Epigenetics of sleep and chronobiology. *Curr. Neurol. Neurosci. Rep.* *14*, 432.
60. Williams, S.R., Aldred, M.A., Der Kaloustian, V.M., Halal, F., Gowans, G., McLeod, D.R., Zondag, S., Toriello, H.V., Magenis, R.E., and Elsea, S.H. (2010). Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. *Am. J. Hum. Genet.* *87*, 219–228.
61. De Leersnyder, H., De Blois, M.C., Claustrat, B., Romana, S., Albrecht, U., Von Kleist-Retzow, J.C., Delobel, B., Viot, G., Lyonnet, S., Vekemans, M., and Munnich, A. (2001). Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome. *J. Pediatr.* *139*, 111–116.
62. Smith, A.C.M., Morse, R.S., Introne, W., and Duncan, W.C., Jr. (2019). Twenty-four-hour motor activity and body temperature patterns suggest altered central circadian timekeeping in Smith-Magenis syndrome, a neurodevelopmental disorder. *Am. J. Med. Genet. A.* *179*, 224–236.
63. Mullegama, S.V., Pugliesi, L., Burns, B., Shah, Z., Tahir, R., Gu, Y., Nelson, D.L., and Elsea, S.H. (2015). MBD5 haploinsufficiency is associated with sleep disturbance and disrupts circadian pathways common to Smith-Magenis and fragile X syndromes. *Eur. J. Hum. Genet.* *23*, 781–789.
64. Nováková, M., Nevšimalová, S., Příhodová, I., Sládek, M., and Sumová, A. (2012). Alteration of the circadian clock in children with Smith-Magenis syndrome. *J. Clin. Endocrinol. Metab.* *97*, E312–E318.
65. Martin, H.C., Jones, W.D., McIntyre, R., Sanchez-Andrade, G., Sanderson, M., Stephenson, J.D., Jones, C.P., Handsaker, J., Gallone, G., Bruntraeger, M., et al.; Deciphering Developmental Disorders Study (2018). Quantifying the contribution of recessive coding variation to developmental disorders. *Science* *362*, 1161–1164.
66. Della Ragione, F., Vacca, M., Fioriniello, S., Pepe, G., and D’Esposito, M. (2016). MECP2, a multi-talented modulator of chromatin architecture. *Brief. Funct. Genomics* *15*, 420–431.
67. Deardorff, M.A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., Saitoh, K., Komata, M., Katou, Y., Clark, D., et al. (2012). HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. *Nature* *489*, 313–317.
68. Tietze, A.L., Blankenburg, M., Hechler, T., Michel, E., Koh, M., Schlüter, B., and Zernikow, B. (2012). Sleep disturbances in children with multiple disabilities. *Sleep Med. Rev.* *16*, 117–127.
69. Gadoth, N., and Oksenberg, A. (2014). Sleep and sleep disorders in rare hereditary diseases: a reminder for the pediatrician, pediatric and adult neurologist, general practitioner, and sleep specialist. *Front. Neurol.* *5*, 133.
70. Chen, L., Mullegama, S.V., Alaimo, J.T., and Elsea, S.H. (2015). Smith-Magenis syndrome and its circadian influence on development, behavior, and obesity - own experience. *Dev Period Med* *19*, 149–156.
71. Trickett, J., Heald, M., Oliver, C., and Richards, C. (2018). A cross-syndrome cohort comparison of sleep disturbance in children with Smith-Magenis syndrome, Angelman syndrome, autism spectrum disorder and tuberous sclerosis complex. *J. Neurodev. Disord.* *10*, 9.
72. Ansar, M., Paracha, S.A., Serretti, A., Sarwar, M.T., Khan, J., Ranza, E., Falconnet, E., Iwaszkiewicz, J., Shah, S.F., Qaisar, A.A., et al. (2019). Biallelic variants in FBXL3 cause intellectual disability, delayed motor development and short stature. *Hum. Mol. Genet.* *28*, 972–979.
73. Kennedy, J., Goudie, D., Blair, E., Chandler, K., Joss, S., McKay, V., Green, A., Armstrong, R., Lees, M., Kamien, B., et al.; DDD Study (2019). KAT6A Syndrome: genotype-phenotype correlation in 76 patients with pathogenic KAT6A variants. *Genet. Med.* *21*, 850–860.
74. Campeau, P.M., Lu, J.T., Dawson, B.C., Fokkema, I.F., Robertson, S.P., Gibbs, R.A., and Lee, B.H. (2012). The KAT6B-related disorders genitopatellar syndrome and Ohdo/SBBYS syndrome have distinct clinical features reflecting distinct molecular mechanisms. *Hum. Mutat.* *33*, 1520–1525.

Supplemental Data

***De Novo* KAT5 Variants Cause a Syndrome with
Recognizable Facial Dysmorphisms, Cerebellar Atrophy,
Sleep Disturbance, and Epilepsy**

Jonathan Humbert, Smrithi Salián, Periklis Makrythanasis, Gabrielle Lemire, Justine Rousseau, Sophie Ehresmann, Thomas Garcia, Rami Alasiri, Armand Bottani, Sylviane Hanquinet, Erin Beaver, Jennifer Heeley, Ann C.M. Smith, Seth I. Berger, Stylianos E. Antonarakis, Xiang-Jiao Yang, Jacques Côté, and Philippe M. Campeau




Figure S1. Generation of K562 cell lines stably expressing KAT5 mutants.

A. Schematic of the strategy used to integrate KAT5 cDNA at the AAVS1 locus. The donor construct and the AAVS1 locus following KAT5 cDNA addition are represented. The first two exons of the PPP1R12C gene are shown as open boxes. Also annotated are the locations of the splice acceptor site (SA), 2A self-cleaving peptide sequence (2A), puromycin resistance gene (Puro), polyadenylation sequence (pA), human phosphoglycerate kinase 1 promoter (hPGK1), and 3xFLAG-2xSTREP tandem affinity tag (Tag); homology arms left and right (HA-L, HA-R) are respectively 800 and 840 bp.

B. Western blots showing flag-tagged KAT5 expression in whole cell extracts from selected K562 clones. Actin was used as a loading control.

C. Western blots on purified native NuA4/TIP60 complexes showing the amount of the complex subunits DMAP1 and Flag-tagged KAT5 present in HAT assays shown in Fig. 2.




Figure S2. Additional qPCR results. Fibroblast qPCR data for genes identified by RNAseq which did not show consistent and significant up or downregulation. β -actin was used as the reference gene. Triplicates were used. Error bars represent standard deviation. P-values were generated by two-way ANOVA with Dunnett's multiple comparisons test.




Figure S3. Snapshots of ChIP-seq from Jacquet et al. 2016 for NuA4/TIP60 subunit EPC1 in K562 cells (EPC1(1-584)-3Flag-2Strep integrated at the AAVS1 locus and empty vector control). Profiles were obtained with Integrated Genomics Viewer with reads per million values and the RPSA gene is shown as positive control for NuA4/TIP60 (GEO accession GSE78027).

Figure S3

Table S1. Additional clinical features

Individual	1	2	3
Demographic information			
Ethnicity	White	White	African-American
Gender	F	M	M
Age at last evaluation	29 years	12 years	16 months
Family history			
Affected family member	No	Cleft lip and palate in cousin once removed	No
Unaffected sibs	1	2 maternal half sibs	No
Consanguinity	No	No	No
Perinatal history			
Perinatal complications	None	None	None
At birth: duration gestation (weeks)	40	38	NA
- Weight, g	3400 (50 th centile)	2740 (5 th -10 th centile)	2275 (2 nd centile)
- Length, cm	48.3 (10 th centile)	47 (3 rd centile)	40.6 (-3.6 SD)
- Head circ., cm	NA	31.5 (3 rd centile)	29.5 (-2.8 SD)
Weight at last visit	80.6 Kg (92 nd centile)	29.7 kg (3 rd centile)	11.2kg (48 th centile)
Height at last visit	150.6cm (3 rd centile, -1.95 SD)	133.5 cm (2 nd centile, -2.1 SD)	71.1 cm (<1 st centile, -2.9 SD)
Head circ at last visit	55 cm (73 rd centile)	50 cm (1 st centile, -2.6 SD)	44.5 cm (1 st centile, -2.2 SD)
Comment	Truncal obesity		
Neurodevelopment			
Developmental delay	Yes, severe	Yes, severe	Yes, severe global developmental delay
Intellectual disability	Yes, FSIQ 40	Yes, IQ 20-30	NA
Speech	Expressive language at 8-year-old level and receptive language at 4-5-year-old skill level	Absent speech	NA

Feeding problems	No	No	Yes – aspiration of thin liquids on swallow study
Hypotonia	Yes	Yes- earlier	No
Medications	Valproic acid	Melatonin slow release GH injections	Risperidone and clonidine
Seizures	Yes	Yes	Yes
Age of first seizure	Adult-onset	infancy	4 months
Type of seizures	Catamenial seizures, grand mal seizures	Variable (partial tonic, late onset infantile spasms, absence) seizures	Generalized tonic clonic and myoclonic seizures
Seizure frequency	Every other month	NA	Multiple per day from 4-10 months of age, then infrequently
Seizure outcome	Seizure-free since 13 years (2004) post hysterectomy	NA	No seizures since 14 months of age
Current anti-epileptic drugs	Valproic acid 1000 mg HS	None	None currently
Anti-epileptic drugs ever tried	Phenytoin, valproic acid 500 mg QID	Valproic acid, lamotrigine, vigabatrin	Previously on Onfi and Keppra
History of Status Epilepticus	No	No	No
History of febrile/complex febrile seizures	No	No	No
Behavioral/psychiatric issues	Yes, disruptive behavior, ADHD tantrums, repetitive, aggressive, impulsive and self-injurious behaviors	Yes, multiple stereotypies, hyperactive and disruptive behavior	Yes, behavior difficulties, tantrums, head banging
Sleep disorder	Yes, severe	Yes, severe	Yes, severe
Neuroradiology	Corpus callosum variant (incomplete development)	Hypoplasia of rostrum and thickening of splenium of corpus callosum; hypoplasia of left caudate nucleus; global progressive cerebellar atrophy (vermis more than hemispheres); small anterior pituitary	Polymicrogyria of right sylvian fissure, cystic dilation of 4th ventricle with inferior cerebellar vermis atrophy, Dandy-Walker variant.

Hearing loss	No, hyperacusis	Mild bilateral asymmetric neurosensory hearing deficit	Mild hearing loss with a conductive component
Vision impairment	Yes	Yes	Intermittent strabismus, no refractive error
If yes, cause	Severe myopia	Divergent strabismus; mild hypermetropia (+2 dioptries) OD; mild myopia (-1.5 dioptries) OS	NA
Malformations and dysmorphisms			
Craniofacial features	SMS-like facial dysmorphism. Round face, flat facial profile, prognathism, depressed nasal bridge, downslanting corners of mouth, low-set ears, almond-shaped eyes	Lateral thinning of eyebrows, macrostomia, prognathism, thick lower lip (N.B. repaired cleft lip/palate), bulbous and asymmetric nose	Round face, flat facial profile, downslanting corners of mouth and upturned nose with depressed nasal bridge, prominent brow ridge. Epiblepharon and epicanthal folds
Cleft palate	No	Unilateral cleft lip and cleft palate	High arched palate and submucous cleft palate
Hand and foot dysmorphisms	Brachydactyly	Bilateral unique palmar creases and bilateral 5th finger clinodactyly. Bilateral pes talus	5th finger clinodactyly bilaterally
Renal anomalies	No	Horseshoe kidney	Not assessed
Urogenital anomalies	Recurrent urinary tract infection.	Bilateral vesico-ureteral reflux (stage III R, stage II L) Unilateral cryptorchidism	Hypospadias, cryptorchidism, concealed penis
MSK anomalies	Leg length discrepancy due to "dry hip socket"	No	No
Cardiac defect	No	No	Perimembranous VSD, dysplastic pulmonary valve with supra- and valvular pulmonary stenosis

Gastrointestinal abnormalities	No	gastroesophageal reflux eosinophilic esophagitis severe constipation	Dysphagia, aspiration of thin liquids Umbilical hernia
Endocrine anomalies	No	Complete GH deficiency since age 2 years, treated by GH injections	No
Surgeries	Hysterectomy to reduce catamenial seizures	-	Ear tubes, hernia repair with ochiopexy
Further information	Low immunoglobulins	-	Intermittent rashes on hands and feet
Genetic tests			
Chromosomal Microarray	Yes, Normal SNP arrays	Yes, normal oligonucleotides array	Likely benign Yp11.222 duplication, 1.0 Mb
Other genetic testing	NI karyotype NI methylation study for PWS NI FISH for SMS NI sequencing of <i>RAI1</i>	NI karyotype NI subtelomere FISH NI subtelomeric MLPA NI sequencing of <i>ZFX1B</i>	None
Biochemical genetics studies	NI urine organic acids NI plasma amino acids NI urine MPS	NA	Creatine kinase 70 U/L (normal)
Hematological anomalies	NA	NA	WBC 8.4 K/ul (NI 5-10), RBC 3.48 M/ul low (NI 3.89-4.97), Hemoglobin 10.3 g/dl low (NI 11-13), hematocrit 31.8% (NI 29-41), platelets 358 K/ul (NI 250-450)

Abbreviations: NI, normal; GH, growth hormone; PWS, Prader-Willi syndrome; SMS, Smith-Magenis syndrome; MPS, mucopolysaccharides; OD, right eye; OS, left eye.

Table S2. Sleep disorder characteristics, based on the Modified Simonds & Parraga Sleep Questionnaire.¹

	Individual 1	Individual 2	Individual 3
Bedtime Resistance	No	No	No
Sleep Onset Delay	No	Yes	Yes (improved by clonidine)
Sleep Anxiety	No	No	No
Night-waking	Yes	Yes	Yes
Parasomnia (talks, grinds teeth, bangs head, quick movements of extremities, tongue biting, enuresis, sleepwalking)	No	No	No
Sleep Disordered Breathing	No	No	No
Daytime sleepiness	Yes	No	No
Inverted circadian rhythm:	High daytime melatonin level (of 46pg/mL), a sign of inversion.	No	No

Table S3. List of primers used for RT-qPCR

Gene	Forward primer (5' to 3')	Reverse primer (5' to 3')
<i>ACTB</i>	GTTGTCGACGACGAGCG	GCACAGAGCCTCGCCTT
<i>LHX9</i>	TACTTCAACGGTACGGGCAC	TCTTCTGCGAGGGTGGATAAG
<i>KIRREL3</i>	TGACGCTACTTTGCGCCAT	GTGGGTAAC TTGAGAGGTCCC
<i>GFPT2</i>	ATGTGCGGAATCTTTGCCTAC	ATCGAGAGCCTTGACTTTCCC
<i>PER1</i>	GCCAACCAGGAATACTACCAGC	GTGTGTA CT CAGACGTGATGTG
<i>HDAC4</i>	CCTGGGAATGTACGACGCC	CCCGTCTTTCCTGCGTAAC
<i>ZNF365</i>	ACGGAATCTGAGGAGGAGCT	ATCACGGACAAAGCCAGAGG
<i>LYPD6B</i>	CTCCTCTCGACCCTACACCA	ATGTGCTTCTTCCGTGGCTG
<i>SPON2</i>	AAGAACCAGTACGTCAGTAACGG	CACAAACGAGACCAGCGAGT
<i>DACT1</i>	TTGAACTGTTTGAGGCGAAGAG	ACTGAACACCGAGTTAGAGGAAT
<i>DAGLA</i>	TGTCACCCTCGGAATGGTTG	GGTTGTAGGTCCGCAGGTTAC
<i>GSN</i>	AACAGCAATCGGTATGAAAGACT	CTGCACCATTGGAGACCTTGT

References

1. Johnson, C.R., Turner, K.S., Foldes, E.L., Malow, B.A., and Wiggs, L. (2012). Comparison of sleep questionnaires in the assessment of sleep disturbances in children with autism spectrum disorders. *Sleep Med* 13, 795-801.